Physician profile
Daniel Mulconrey
NPI 1710914064
$64,755.48
in general payments reported to CMS, 2019-2025
12 companies · $11K in 2025
The $11K reported for 2025 was more than what a typical Orthopaedic Surgery of The Spine provider received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,573 · 2020: $9,172 · 2021: $15K · 2022: $5,875 · 2023: $5,744 · 2024: $11K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Travel and Lodging: $8,817 · Food and Beverage: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,262.50 |
| Travel and Lodging | $8,817.16 |
| Food and Beverage | $1,345.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alphatec Spine, INC | $39,139.08 | 2020-2025 | Other - Miscellaneous, Battalion Tlif - PC, Solus Alif |
| Medtronic USA, INC. | $11,623.24 | 2019-2020 | |
| Medtronic, INC. | $8,587.63 | 2021-2023 | Artic-L 3d Ti Spinal System With Tionic Technology, Cd Horizon Spinal System, Unid_pass |
| Life Spine, INC. | $2,279.81 | 2019 | |
| Arthrex, INC. | $1,525.83 | 2025 | |
| Prism Medical | $1,110.72 | 2024-2025 | |
| Nuvasive, INC. | $261.92 | 2019-2023 | X-Core, Alif |
| Ferring Pharmaceuticals INC. | $108.21 | 2019-2025 | Euflexxa |
| Depuy Synthes Sales INC. | $64.83 | 2024-2025 | Monovisc, Symphony |
| Orthofix Medical, INC. | $28.50 | 2023 | Physio-Stim, Spinal-Stim |
| Bioventus LLC | $12.91 | 2019 | |
| Pfizer INC. | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mulconrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.